Ftse Mib
34.301,58
-1,06%
DAX
18.405,64
-1,10%
S&P 500
5.261,50
-0,41%
NASDAQ
16.761,67
-0,40%
Bitcoin
71.014,03
3,21%
Registration Strip Icon for alerts Registrati per avvisi in tempo reale, portafoglio personalizzato e movimenti di mercato.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Inhibrx Biosciences Inc (INBX) Inhibrx Biosciences Inc (INBX) Notizie

INBX

Inhibrx Biosciences (INBX)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:INBX
DataOraFonteTitoloSimboloCompagnia
31/05/202422:30Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:INBXInhibrx Biosciences Inc
30/05/202422:34Edgar (US Regulatory)Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendmentsNASDAQ:INBXInhibrx Biosciences Inc
30/05/202422:32Edgar (US Regulatory)Form POSASR - Post-effective Amendment to an automatic shelf registration statementNASDAQ:INBXInhibrx Biosciences Inc
30/05/202422:13Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:INBXInhibrx Biosciences Inc
28/05/202422:55Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:INBXInhibrx Biosciences Inc
24/05/202422:44Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:INBXInhibrx Biosciences Inc
24/05/202422:00PR Newswire (US)Inhibrx Inc. Stockholders Approve Sale of INBRX-101 to SanofiNASDAQ:INBXInhibrx Biosciences Inc
21/05/202403:48Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:INBXInhibrx Biosciences Inc
11/05/202400:36PR Newswire (US)Inhibrx, Inc. Announces Updated When-Issued Trading Date for Anticipated Spin-OffNASDAQ:INBXInhibrx Biosciences Inc
08/05/202422:37PR Newswire (US)Inhibrx, Inc. Announces Record Date and Expected Distribution Time for Anticipated Spin-Off and the Expected Merger Effective Time for Anticipated MergerNASDAQ:INBXInhibrx Biosciences Inc
29/02/202423:26Edgar (US Regulatory)Form PREM14A - Preliminary proxy statements relating to merger or acquisitionNASDAQ:INBXInhibrx Biosciences Inc
28/02/202415:15PR Newswire (US)Inhibrx Reports Fourth Quarter and Fiscal Year 2023 Financial ResultsNASDAQ:INBXInhibrx Biosciences Inc
28/02/202415:10Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:INBXInhibrx Biosciences Inc
14/02/202422:12Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:INBXInhibrx Biosciences Inc
26/01/202418:12PR Newswire (US)Kuehn Law Encourages DOC, BATL, KAMN, and INBX Investors to Contact Law FirmNASDAQ:INBXInhibrx Biosciences Inc
23/01/202412:05Dow Jones NewsSanofi to Buy Assets From Inhibrx in Deal Valued at Up to $2.2 Billion -- UpdateNASDAQ:INBXInhibrx Biosciences Inc
23/01/202411:40IH Market NewsWall Street Highlights: Vroom Shuts Down Online Car Sales, Ericsson Warns of Decline Outside China, and MoreNASDAQ:INBXInhibrx Biosciences Inc
23/01/202407:00PR Newswire (US)Inhibrx Announces Sale of INBRX-101 to Sanofi for an aggregate value of up to $2.2BNASDAQ:INBXInhibrx Biosciences Inc
09/11/202322:01Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:INBXInhibrx Biosciences Inc
09/11/202322:00PR Newswire (US)Inhibrx Reports Third Quarter 2023 Financial Results and Recent Corporate HighlightsNASDAQ:INBXInhibrx Biosciences Inc
02/11/202314:15PR Newswire (US)Inhibrx Announces Preliminary Data from the Phase 1 Trial of INBRX-109 for the Treatment of Ewing SarcomaNASDAQ:INBXInhibrx Biosciences Inc
18/10/202322:00PR Newswire (US)Inhibrx Announces Participation in Upcoming Scientific ConferencesNASDAQ:INBXInhibrx Biosciences Inc
19/09/202322:00PR Newswire (US)Inhibrx Retains Rights to INBRX-101 for the Treatment of Alpha-1 Antitrypsin Deficiency Outside of the United States and CanadaNASDAQ:INBXInhibrx Biosciences Inc
31/08/202322:06Edgar (US Regulatory)Form D - Notice of Exempt Offering of SecuritiesNASDAQ:INBXInhibrx Biosciences Inc
29/08/202315:00PR Newswire (US)Inhibrx Announces $200 Million Private Placement FinancingNASDAQ:INBXInhibrx Biosciences Inc
07/08/202322:00PR Newswire (US)Inhibrx Reports Second Quarter 2023 Financial Results and Recent Corporate HighlightsNASDAQ:INBXInhibrx Biosciences Inc
30/05/202322:11Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:INBXInhibrx Biosciences Inc
30/05/202315:46Dow Jones NewsInhibrx Granted FDA Fast Track Designation for INBRX-101NASDAQ:INBXInhibrx Biosciences Inc
30/05/202315:04Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:INBXInhibrx Biosciences Inc
30/05/202315:00PR Newswire (US)Inhibrx Granted Fast Track Designation for INBRX-101 for the Treatment of Alpha-1 Antitrypsin DeficiencyNASDAQ:INBXInhibrx Biosciences Inc
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:INBX

La tua Cronologia

USOTC
BCDMF
Kuuhubb (CE)
NASDAQI
XBCIGTR
Bitwise Crypto Innovator...
USOTC
KMMIF
Rua Gold (PK)
XE
PRAE
Amundi Luxembourg
LSE
TCF
Theracryf
NASDAQ
FUOVAX
Banking Opportunity Port...
LSE
IDTK
Ishr Turkey
LSE
QI21
Morg.st.b.v 24
NASDAQ
FMCIU
Forum Merger II
MRTX
DWEETH
Digital World Exchange
BIT
P1W502
NLBNPIT1W502 20241220 35
TSXV
HOC
Hunter Technology
NYSE
USB-G.CL
NASDAQ
FMNGX
Fidelity Advisor Conserv...
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network